These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17560435)

  • 1. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
    Rodríguez-Reimúndes E; Perazzo F; Vilches AR
    Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
    Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
    Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib as adjuvant therapy for renal cell carcinoma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 6. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 7. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
    Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
    Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of antiangiogenic therapy-induced hypertension.
    de Jesus-Gonzalez N; Robinson E; Moslehi J; Humphreys BD
    Hypertension; 2012 Sep; 60(3):607-15. PubMed ID: 22851729
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
    De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
    J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
    Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatigue with sunitinib-induced hypothyroidism.
    Senior K
    Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib and hypothyroidism.
    Wolter P; Dumez H; Schöffski P
    N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
    [No Abstract]   [Full Text] [Related]  

  • 16. Posterior reversible encephalopathy syndrome during sunitinib therapy.
    Cumurciuc R; Martinez-Almoyna L; Henry C; Husson H; de Broucker T
    Rev Neurol (Paris); 2008; 164(6-7):605-7. PubMed ID: 18565360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
    Gyawali B; Ando Y
    Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib-induced thyrotoxicosis - a not so rare entity.
    Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
    Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellowish nail pigmentation caused by sunitinib.
    Espinosa Lara P; Bueno C; Aranegui B; Vargas-Machuca I; Jiménez Reyes J
    Int J Dermatol; 2016 Aug; 55(8):e462-3. PubMed ID: 26971887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.